No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
1- deoxygalactonojirimycin |
- |
- |
- |
- |
1件: 19 |
2 |
1-deoxygalactonojirimycin |
Migalastat |
D10359 |
- |
- |
1件: 19 |
3 |
1-deoxygalactonojirimycin hydrochloride |
Migalastat |
D10359 |
- |
- |
1件: 19 |
4 |
12s-it |
- |
- |
- |
- |
1件: 19 |
5 |
15 o water |
Water |
D00001 |
- |
- |
1件: 19 |
6 |
2-aminoethanethiol |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
7 |
2-hydroxypropyl-beta-cyclodextrin |
Hydroxypropyl betadex |
- |
- |
- |
1件: 19 |
8 |
500 0500 0 |
- |
- |
- |
- |
1件: 19 |
9 |
89 zirconium recombinant human alpha-n-acetylglucosaminidase (rhnaglu) (radiolabeled) |
- |
- |
- |
- |
1件: 19 |
10 |
89zr-sbc-103 |
- |
- |
- |
- |
1件: 19 |
11 |
[14c] at1001 |
- |
- |
- |
- |
1件: 19 |
12 |
A (migalastat) |
Migalastat |
D10359 |
- |
- |
1件: 19 |
13 |
Aav2/8.tbg.harsb |
- |
- |
- |
- |
1件: 19 |
14 |
Aav2cuhcln2 (3x10^12 particle units) |
- |
- |
- |
- |
1件: 19 |
15 |
Aav9-cag-coh-sgsh |
- |
- |
- |
- |
1件: 19 |
16 |
Aav9-glb1 |
- |
- |
- |
- |
1件: 19 |
17 |
Aavrh.10-hmpsiiia |
- |
- |
- |
- |
1件: 19 |
18 |
Aavrh.10cuarsa |
- |
- |
- |
- |
1件: 19 |
19 |
Aavrh.10cucln2 |
- |
- |
- |
- |
1件: 19 |
20 |
Aavrh.10cuhcln2 vector 2.85x10^11 genome copies |
- |
- |
- |
- |
1件: 19 |
21 |
Aavrh.10cuhcln2 vector 9.0x10^11 genome copies |
- |
- |
- |
- |
1件: 19 |
22 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
23 |
Abo-102 |
- |
- |
- |
- |
1件: 19 |
24 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
25 |
Act-434964 |
- |
- |
- |
- |
1件: 19 |
26 |
Adalimumab |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
15件: 19, 37, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 |
27 |
Adalimumab injection [humira] |
Adalimumab |
D02597 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 19 |
28 |
Adeno-associated viral (aav) serotype 8 (aav2/8) vector with liver-specific thyroxine-binding globulin (tbg) promoter, driving the expression of the human arsb gene |
- |
- |
- |
- |
1件: 19 |
29 |
Adeno-associated virus serotype 2/6 encoding human iduronidase (hidua) gene donor vector, sb-a6p-hrl donor vector |
- |
- |
- |
- |
1件: 19 |
30 |
Adeno-associated virus serotype 2/6 encoding left side-zinc finger nuclease (zfn1), sb-a6p-zleft vector |
Zinc |
- |
- |
- |
1件: 19 |
31 |
Adeno-associated virus serotype 2/6 encoding right side-zinc finger nuclease (zfn2), sb-a6p-zright vector |
Zinc |
- |
- |
- |
1件: 19 |
32 |
Administration |
- |
- |
- |
- |
1件: 19 |
33 |
Afegostat |
Afegostat |
D09576 |
- |
- |
1件: 19 |
34 |
Afegostat tartrate |
Afegostat |
D09576 |
- |
- |
1件: 19 |
35 |
Agalsidase |
- |
- |
- |
- |
1件: 19 |
36 |
Agalsidase alfa |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
37 |
Agalsidase alpha |
- |
- |
- |
- |
1件: 19 |
38 |
Agalsidase beta |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
39 |
Agalsidase beta (gz419828) |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
40 |
Agalsidase beta (recombinant form) |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
41 |
Agt-181 |
- |
- |
- |
- |
1件: 19 |
42 |
Agt-181 (hirmab-idua) |
- |
- |
- |
- |
1件: 19 |
43 |
Agt-182 |
- |
- |
- |
- |
1件: 19 |
44 |
Aldurazyme |
Laronidase |
D04670 |
1件: IDUA |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
45 |
Aldurazyme (laronidase) |
Laronidase |
D04670 |
1件: IDUA |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
46 |
Aldurazyme (recombinant human alpha-l-iduronidase) |
- |
- |
- |
- |
1件: 19 |
47 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
13件: 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
48 |
Alendronate |
Alendronic acid |
D00939, D07119 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
7件: 19, 41, 46, 50, 271, 274, 299 |
49 |
Alendronate sodium |
Alendronic acid |
D00939, D07119 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
2件: 19, 299 |
50 |
Alpha-galactosidase a |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
51 |
Ambroxol |
Ambroxol |
D07442 |
- |
- |
2件: 6, 19 |
52 |
Anakinra |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
15件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
53 |
Angiotensin |
Angiotensin ii |
D00150, D02014 |
2件: AGTR1, AGTR2 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
7件: 17, 19, 46, 66, 86, 222, 224 |
54 |
Arimoclomol |
Arimoclomol |
D11374 |
- |
- |
3件: 2, 15, 19 |
55 |
Arylsulfatase a |
- |
- |
- |
- |
1件: 19 |
56 |
At1001 |
- |
- |
- |
- |
1件: 19 |
57 |
At1001 (migalastat hydrochloride) |
Migalastat |
D10359 |
- |
- |
1件: 19 |
58 |
At1001 150 mg |
- |
- |
- |
- |
1件: 19 |
59 |
At2101 |
- |
- |
- |
- |
1件: 19 |
60 |
Ataluren |
Ataluren |
D09323 |
- |
- |
6件: 19, 113, 140, 246, 299, 329 |
61 |
Autologous cd34+ cells transduced with a lentiviral vector encoding the arsa cdna |
- |
- |
- |
- |
1件: 19 |
62 |
Avr-rd-01 |
- |
- |
- |
- |
1件: 19 |
63 |
Avr-rd-02 |
- |
- |
- |
- |
1件: 19 |
64 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
65 |
Azathioprine (aza) |
Azathioprine |
D00238, D03033 |
- |
- |
2件: 19, 97 |
66 |
B (migalastat) |
Migalastat |
D10359 |
- |
- |
1件: 19 |
67 |
Beta-cyclodextrin |
Betadex |
D02401 |
- |
- |
1件: 19 |
68 |
Bhp001 |
- |
- |
- |
- |
1件: 19 |
69 |
Biological assays |
- |
- |
- |
- |
1件: 19 |
70 |
Biopsy |
- |
- |
- |
- |
2件: 19, 51 |
71 |
Blood sampling |
- |
- |
- |
- |
4件: 13, 19, 51, 96 |
72 |
Bmn 110 |
- |
- |
- |
- |
1件: 19 |
73 |
Bmn 190 |
- |
- |
- |
- |
1件: 19 |
74 |
Bmn 250 |
- |
- |
- |
- |
1件: 19 |
75 |
Bmn190 recombinant human tripeptidyl peptidase-1 (rhtpp1) |
- |
- |
- |
- |
1件: 19 |
76 |
Brineura |
Cerliponase alfa |
D10813 |
1件: TPP1 |
1件: Lysosome |
1件: 19 |
77 |
Busilvex |
- |
- |
- |
- |
4件: 19, 36, 60, 65 |
78 |
Busulfan |
Busulfan |
D00248 |
- |
- |
13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 |
79 |
Busulfan, cyclophosphamide, antithymocyte globulin |
Cyclophosphamide |
D00287, D07760 |
- |
- |
2件: 19, 20 |
80 |
Busulfan, cyclophosphamide, atg |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 19 |
81 |
C (migalastat) |
Migalastat |
D10359 |
- |
- |
1件: 19 |
82 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
83 |
Calcium carbonate |
Calcium carbonate |
D00932, D10802 |
- |
- |
7件: 13, 19, 46, 75, 96, 235, 299 |
84 |
Cald hr-d (high-risk, regimen c) |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
85 |
Cald hr-d (high-risk, regimen d) |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
86 |
Cald sr-a (standard-risk, regimen a) |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
87 |
Cald sr-b (standard-risk, regimen b) |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
88 |
Campath-1h |
Alemtuzumab |
D02802 |
- |
- |
6件: 19, 20, 60, 234, 285, 326 |
89 |
Capsaicin |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
6件: 2, 6, 19, 86, 113, 226 |
90 |
Carbonate |
Carbonate ion |
- |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
91 |
Ceredase™ |
- |
- |
- |
- |
1件: 19 |
92 |
Cerezyme |
Imiglucerase |
D02810, D03020 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
93 |
Cerezyme (imiglucerase for injection) |
Imiglucerase |
D02810, D03020 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
94 |
Cerezyme® |
- |
- |
- |
- |
1件: 19 |
95 |
Cerliponase alfa |
Cerliponase alfa |
D10813 |
1件: TPP1 |
1件: Lysosome |
1件: 19 |
96 |
Chemically modified recombinant human sulfamidase |
- |
- |
- |
- |
1件: 19 |
97 |
Cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 |
98 |
Cholesterol |
Cholesterol |
D00040 |
- |
- |
7件: 19, 90, 160, 259, 261, 301, 310 |
99 |
Clofarabine |
Clofarabine |
D03546 |
3件: POLA1, POLA2, RRM1 |
6件: DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
100 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
101 |
Cyclosporine |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
33件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
102 |
Cyclosporine a |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
8件: 19, 20, 36, 49, 53, 58, 60, 234 |
103 |
Cyclosporine a (csa) |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 19 |
104 |
Cystadane anhydrous |
- |
- |
- |
- |
1件: 19 |
105 |
Cystadrops |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
106 |
Cystadrops 0.55% eye drops, solution |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
107 |
Cystagon |
Cysteamine |
D03634, D03635 |
- |
- |
3件: 8, 19, 299 |
108 |
Cystagon® |
- |
- |
- |
- |
1件: 19 |
109 |
Cystagon® (cysteamine bitartrate) |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
110 |
Cysteamine |
Cysteamine |
D03634, D03635 |
- |
- |
4件: 8, 19, 21, 299 |
111 |
Cysteamine (mercaptamine) viscous solution |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
112 |
Cysteamine bitartrate |
Cysteamine |
D03634, D03635 |
- |
- |
4件: 8, 19, 21, 299 |
113 |
Cysteamine bitartrate (inn: mercaptamine bitartrate ) |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
114 |
Cysteamine bitartrate delayed-release capsules (rp103) |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
115 |
Cysteamine hydrochloride |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
116 |
Cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
117 |
D (migalastat) |
Migalastat |
D10359 |
- |
- |
1件: 19 |
118 |
Dried blood spot (dbs) sampling |
- |
- |
- |
- |
1件: 19 |
119 |
Drx005b |
- |
- |
- |
- |
1件: 19 |
120 |
Duoc-01 |
- |
- |
- |
- |
2件: 19, 20 |
121 |
E (migalastat) |
Migalastat |
D10359 |
- |
- |
1件: 19 |
122 |
Elaprase |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
123 |
Elaprase for intravenous (iv) infusion |
- |
- |
- |
- |
1件: 19 |
124 |
Elaprase_0.5mg/kg |
- |
- |
- |
- |
1件: 19 |
125 |
Elelyso |
Taliglucerase alfa |
D09675 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
126 |
Elelyso 60 units/kg |
- |
- |
- |
- |
1件: 19 |
127 |
Eliglustat |
Eliglustat |
D09893 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
128 |
Eliglustat gz385660 |
Eliglustat |
D09893 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
129 |
Eliglustat tartrate |
Eliglustat |
D09893 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
130 |
Elosulfase alfa |
Elosulfase alfa |
D10333 |
1件: GALNS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
131 |
Elosulfase alfa 1 mg/ml intravenous solution [vimizim] |
Elosulfase alfa |
D10333 |
1件: GALNS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
132 |
Elx-02 |
- |
- |
- |
- |
2件: 19, 299 |
133 |
Enalapril |
Enalapril |
D00621, D07892 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
4件: 19, 46, 66, 113 |
134 |
Enalapril and other angiotensin converting enzyme inhibitors |
Enalapril |
D00621, D07892 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
1件: 19 |
135 |
Enriched hematopoetic stem cell infusion |
- |
- |
- |
- |
3件: 13, 19, 284 |
136 |
Enzyme replacement |
- |
- |
- |
- |
1件: 19 |
137 |
Enzyme replacement therapy (agalsidase alpha (replagal®)) |
- |
- |
- |
- |
1件: 19 |
138 |
Enzyme replacement therapy (ert) |
- |
- |
- |
- |
1件: 19 |
139 |
Fabrazyme |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
140 |
Fabrazyme (agalsidase beta) |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
141 |
Fluorescein |
Fluorescein |
D01261, D02024 |
- |
- |
2件: 19, 97 |
142 |
Ga-gcb |
Velaglucerase alfa |
D09029 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
143 |
Gabapentin |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
5件: 6, 13, 19, 70, 298 |
144 |
Galsulfase |
Galsulfase |
D06565 |
1件: ARSB |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
145 |
Gc1111_0.5mg/kg |
- |
- |
- |
- |
1件: 19 |
146 |
Gc1111_1.0mg/kg |
- |
- |
- |
- |
1件: 19 |
147 |
Gc1119 |
- |
- |
- |
- |
1件: 19 |
148 |
Gene activated human glucocerebrosidase |
- |
- |
- |
- |
1件: 19 |
149 |
Gene-activated human glucocerebrosidase |
- |
- |
- |
- |
1件: 19 |
150 |
Genistein |
Genistein |
D11680 |
- |
- |
2件: 19, 299 |
151 |
Genistein aglycone |
Genistein |
D11680 |
- |
- |
1件: 19 |
152 |
Genz-112638 |
- |
- |
- |
- |
1件: 19 |
153 |
Genz-682452 |
Venglustat |
D11633 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
2件: 19, 67 |
154 |
Genz-682452-aa |
Venglustat |
D11633 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
155 |
Genz-682452-au |
Venglustat |
D11633 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
2件: 19, 67 |
156 |
Glucocerebrosidase |
- |
- |
- |
- |
1件: 19 |
157 |
Gr181413a/at1001 capsule |
- |
- |
- |
- |
1件: 19 |
158 |
Gr181413a/at1001 solution |
- |
- |
- |
- |
1件: 19 |
159 |
Growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
11件: 2, 13, 19, 46, 78, 96, 191, 193, 195, 265, 299 |
160 |
Gsk2788723 |
- |
- |
- |
- |
1件: 19 |
161 |
Gz/sar402671 |
- |
- |
- |
- |
2件: 6, 19 |
162 |
Gz402671 |
- |
- |
- |
- |
2件: 19, 67 |
163 |
Gz402671 / sar402671 |
- |
- |
- |
- |
1件: 19 |
164 |
Hematopoetic stem cell transplantation |
- |
- |
- |
- |
5件: 19, 65, 120, 160, 326 |
165 |
Hematopoietic stem cell infusion |
- |
- |
- |
- |
2件: 19, 20 |
166 |
Hematopoietic stem cell transplantation |
- |
- |
- |
- |
12件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 |
167 |
Hgt-1110 |
- |
- |
- |
- |
1件: 19 |
168 |
Hgt-1111 |
- |
- |
- |
- |
1件: 19 |
169 |
Hgt-1410 |
- |
- |
- |
- |
1件: 19 |
170 |
Hgt-2310 |
- |
- |
- |
- |
1件: 19 |
171 |
Hucns-sc |
- |
- |
- |
- |
1件: 19 |
172 |
Human glucocerebrosidase (prgcd) |
Taliglucerase alfa |
D09675 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
173 |
Human placental derived stem cell |
- |
- |
- |
- |
4件: 19, 20, 60, 284 |
174 |
Hunterase |
- |
- |
- |
- |
1件: 19 |
175 |
Hydroxypropyl-beta-cyclodextrin |
Betadex |
D02401 |
- |
- |
1件: 19 |
176 |
Hydroxypropyl-ß-cyclodextrin |
- |
- |
- |
- |
1件: 19 |
177 |
Hydroxyurea |
Hydroxyurea |
D00341 |
1件: RRM2 |
6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
8件: 3, 13, 19, 20, 65, 85, 86, 284 |
178 |
Ib1001 |
- |
- |
- |
- |
1件: 19 |
179 |
Iduronate-2-sulfatase enzyme replacement therapy |
- |
- |
- |
- |
1件: 19 |
180 |
Idursulfase |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
181 |
Idursulfase (i2s) |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
182 |
Idursulfase beta |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
183 |
Idursulfase it (1 mg) |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
184 |
Idursulfase it (10 mg) |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
185 |
Idursulfase it (30 mg) |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
186 |
Idursulfase(12s)-it |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
187 |
Idursulfase-it |
Idursulfase |
D04499 |
1件: IDS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
188 |
Igf2 |
Insulin-like growth factor ii |
- |
- |
- |
1件: 19 |
189 |
Imd preparative regimen |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
190 |
Imiglucerasa |
Imiglucerase |
D02810, D03020 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
191 |
Imiglucerase |
Imiglucerase |
D02810, D03020 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
192 |
Imiglucerase gz437843 |
Imiglucerase |
D02810, D03020 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
193 |
Imiglucérase (drug) pharmacokinetics |
- |
- |
- |
- |
1件: 19 |
194 |
Intrathecal recombinant human alpha iduronidase |
- |
- |
- |
- |
1件: 19 |
195 |
Iohexol |
Iohexol |
D01817 |
- |
- |
1件: 19 |
196 |
Irt laronidase |
Laronidase |
D04670 |
1件: IDUA |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
197 |
Isofagamine tartrate |
- |
- |
- |
- |
1件: 19 |
198 |
Isu302 |
- |
- |
- |
- |
1件: 19 |
199 |
Iv migalastat hcl |
Migalastat |
D10359 |
- |
- |
1件: 19 |
200 |
Iva 336 |
- |
- |
- |
- |
1件: 19 |
201 |
Jr-141 |
- |
- |
- |
- |
1件: 19 |
202 |
Kanuma |
Sebelipase alfa |
D10377 |
1件: LIPA |
3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
1件: 19 |
203 |
Lamazym |
Velmanase alfa |
D11024 |
1件: MAN2B1 |
2件: Lysosome, Other glycan degradation |
1件: 19 |
204 |
Laronidase |
Laronidase |
D04670 |
1件: IDUA |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
205 |
Laronidase ert |
Laronidase |
D04670 |
1件: IDUA |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
206 |
Ledipasvir |
Ledipasvir |
D10442 |
- |
- |
1件: 19 |
207 |
Ledipasvir/sofosbuvir |
Ledipasvir, Sofosbuvir |
D10366, D10442 |
- |
- |
1件: 19 |
208 |
Lentivirus alpha-gal a transduced stem cells |
- |
- |
- |
- |
1件: 19 |
209 |
Lentivirus-mediated delivery of arsa to the cns. |
- |
- |
- |
- |
1件: 19 |
210 |
Leucovorin |
Leucovorin |
D01211, D07986, D07987 |
- |
- |
2件: 19, 46 |
211 |
Lithium carbonate |
Lithium carbonate |
D00801 |
- |
- |
5件: 2, 13, 17, 19, 127 |
212 |
Losartan |
Losartan |
D00357, D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
213 |
Lucerastat |
Lucerastat |
D11439 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
214 |
Lys-saf302 |
- |
- |
- |
- |
1件: 19 |
215 |
Lysodase |
- |
- |
- |
- |
1件: 19 |
216 |
Lysosomal acid lipase, esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa) |
Cholesterol |
D00040 |
- |
- |
1件: 19 |
217 |
Medication to suppress the immune system |
- |
- |
- |
- |
1件: 19 |
218 |
Melphalan |
Melphalan |
D00369 |
- |
- |
14件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
219 |
Mepsevii |
Vestronidase alfa |
D11004 |
1件: GUSB |
6件: Drug metabolism - other enzymes, Glycosaminoglycan degradation, Lysosome, Metabolic pathways, Pentose and glucuronate interconversions, Porphyrin and chlorophyll metabolism |
1件: 19 |
220 |
Mercaptamine |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
221 |
Mercaptamine bitartrate |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
222 |
Mercaptamine hydrochloride |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
223 |
Mercaptamine, mercamine, 2-aminoethanethiol |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 19 |
224 |
Metazym |
- |
- |
- |
- |
1件: 19 |
225 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
226 |
Migalastat |
Migalastat |
D10359 |
- |
- |
1件: 19 |
227 |
Migalastat hcl |
Migalastat |
D10359 |
- |
- |
1件: 19 |
228 |
Migalastat hcl 150 mg |
Migalastat |
D10359 |
- |
- |
1件: 19 |
229 |
Migalastat hydrochloride |
Migalastat |
D10359 |
- |
- |
1件: 19 |
230 |
Miglustat |
Miglustat |
D05032 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
3件: 19, 256, 299 |
231 |
Miglustat (zavesca) |
Miglustat |
D05032 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
232 |
Monitor |
Methamidophos |
- |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
233 |
Moss-agal (recombinant human alpha-galactosidase a produced in moss) |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
234 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
235 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
236 |
Mycophenylate mofetil |
- |
- |
- |
- |
2件: 19, 20 |
237 |
N acetyl cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
1件: 19 |
238 |
N-acetyl cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
5件: 13, 19, 85, 88, 296 |
239 |
N-acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
10件: 6, 13, 19, 20, 49, 58, 85, 111, 164, 299 |
240 |
N-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
1件: 19 |
241 |
N-acetylgalactosamine-6-sulfatase |
Elosulfase alfa |
D10333 |
1件: GALNS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
242 |
Naglazyme |
Galsulfase |
D06565 |
1件: ARSB |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
243 |
Naglazyme® |
- |
- |
- |
- |
1件: 19 |
244 |
Non applicable |
- |
- |
- |
- |
2件: 10, 19 |
245 |
Odiparcil |
Odiparcil |
- |
- |
- |
1件: 19 |
246 |
Ogt 918 |
- |
- |
- |
- |
2件: 19, 299 |
247 |
Ogt918 |
- |
- |
- |
- |
1件: 19 |
248 |
Ogt923 |
- |
- |
- |
- |
1件: 19 |
249 |
Olenasufligene relduparvovec |
- |
- |
- |
- |
1件: 19 |
250 |
Omnipaque |
Iohexol |
D01817 |
- |
- |
1件: 19 |
251 |
Oral migalastat hcl |
Migalastat |
D10359 |
- |
- |
1件: 19 |
252 |
Osteopetrosis haploidentical only preparative regimen |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
253 |
Osteopetrosis only preparative regimen |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
254 |
Paricalcitol |
Paricalcitol |
D00930 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
3件: 19, 66, 218 |
255 |
Pegunigalsidase alfa |
Pegunigalsidase alfa |
D11685 |
- |
- |
1件: 19 |
256 |
Pegunigalsidase alpha |
- |
- |
- |
- |
1件: 19 |
257 |
Pentosan polysulfat sp 54® injection solution |
Pentosan polysulfate |
D05428 |
- |
- |
1件: 19 |
258 |
Pentosan polysulfate |
Pentosan polysulfate |
D05428 |
- |
- |
3件: 19, 26, 226 |
259 |
Pentosan polysulfate sodium |
Pentosan polysulfate |
D05428 |
- |
- |
1件: 19 |
260 |
Pentosan polysulphate sp54 |
Pentosan polysulfate |
D05428 |
- |
- |
1件: 19 |
261 |
Pentosan polysulphate sp54® |
Pentosan polysulfate |
D05428 |
- |
- |
1件: 19 |
262 |
Plant cell expressed recombinant glucocerebrosidase (prgcd) |
Taliglucerase alfa |
D09675 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
263 |
Prgcd |
Taliglucerase alfa |
D09675 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
264 |
Prx-102 |
- |
- |
- |
- |
1件: 19 |
265 |
Prx-102 (pegunigalsidase alfa) |
Pegunigalsidase alfa |
D11685 |
- |
- |
1件: 19 |
266 |
Prx-112 |
- |
- |
- |
- |
1件: 19 |
267 |
Ptc124 |
- |
- |
- |
- |
4件: 19, 113, 246, 299 |
268 |
Pyrimethamine |
Pyrimethamine |
D00488 |
- |
- |
4件: 2, 4, 19, 65 |
269 |
Raav2/5-hnaglu |
- |
- |
- |
- |
1件: 19 |
270 |
Raav2/6 left zfn vector |
- |
- |
- |
- |
1件: 19 |
271 |
Raav2/6 right zfn vector |
- |
- |
- |
- |
1件: 19 |
272 |
Raav9.cmv.hnaglu |
- |
- |
- |
- |
1件: 19 |
273 |
Recombinant alpha-galactosidase a |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
274 |
Recombinant human alpha-galactosidase |
- |
- |
- |
- |
1件: 19 |
275 |
Recombinant human alpha-mannosidase |
- |
- |
- |
- |
1件: 19 |
276 |
Recombinant human alpha-n-acetylglucosaminidase (rhnaglu) |
- |
- |
- |
- |
1件: 19 |
277 |
Recombinant human arylsulfatase a |
- |
- |
- |
- |
1件: 19 |
278 |
Recombinant human arylsulfatase a (rhasa) |
- |
- |
- |
- |
1件: 19 |
279 |
Recombinant human arylsulfatase a (rhasa, |
- |
- |
- |
- |
1件: 19 |
280 |
Recombinant human arysulfatase b, recombinant human n-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
1件: 19 |
281 |
Recombinant human derived macrophage-targeted beta-glucocerebrosidase |
- |
- |
- |
- |
1件: 19 |
282 |
Recombinant human derived macrophage-targeted ß-glucocerebrosidase |
- |
- |
- |
- |
1件: 19 |
283 |
Recombinant human glucerebrosidase |
- |
- |
- |
- |
1件: 19 |
284 |
Recombinant human glucocerebrosidase |
- |
- |
- |
- |
1件: 19 |
285 |
Recombinant human heparan n-sulfatase |
- |
- |
- |
- |
1件: 19 |
286 |
Recombinant human heparan n-sulfatase (rhhns) |
- |
- |
- |
- |
1件: 19 |
287 |
Recombinant human lysosomal acid lipase |
- |
- |
- |
- |
1件: 19 |
288 |
Recombinant human lysosomal acid lipase (rhlal) |
- |
- |
- |
- |
1件: 19 |
289 |
Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa) |
Cholesterol |
D00040 |
- |
- |
1件: 19 |
290 |
Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa) |
Cholesterol |
D00040 |
- |
- |
1件: 19 |
291 |
Recombinant human lysosomal alpha-mannosidase |
- |
- |
- |
- |
1件: 19 |
292 |
Recombinant human n-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
1件: 19 |
293 |
Recombinant human n-acetylgalactosamine 6-sulfatase, bmn 110 drug substance |
- |
- |
- |
- |
1件: 19 |
294 |
Recombinant human n-acetylgalactosamine-6-sulfatase (rhgalns) |
Elosulfase alfa |
D10333 |
1件: GALNS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
295 |
Recombinant human n-acetylgalactosamine-6-sulfatase, bmn 110 drug substance |
Elosulfase alfa |
D10333 |
1件: GALNS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
296 |
Recombinant human tripeptidyl peptidase-1 |
- |
- |
- |
- |
1件: 19 |
297 |
Recombinant human tripeptidyl peptidase-1 (rhtpp1) |
- |
- |
- |
- |
1件: 19 |
298 |
Reduced intensity conditioning |
- |
- |
- |
- |
2件: 19, 65 |
299 |
Reminder capsules |
- |
- |
- |
- |
1件: 19 |
300 |
Replagal |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
301 |
Replagal (agalsidase alfa) |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
302 |
Replagal agalsidase alfa |
Agalsidase beta |
D03228 |
1件: GLA |
6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
303 |
Rh growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 19 |
304 |
Rharsa |
- |
- |
- |
- |
1件: 19 |
305 |
Rhasa |
- |
- |
- |
- |
1件: 19 |
306 |
Rhasm |
- |
- |
- |
- |
1件: 19 |
307 |
Rhidu (recombinant human-alpha-l-iduronidase) |
- |
- |
- |
- |
1件: 19 |
308 |
Rhlaman |
Velmanase alfa |
D11024 |
1件: MAN2B1 |
2件: Lysosome, Other glycan degradation |
1件: 19 |
309 |
Rhnaglu |
- |
- |
- |
- |
1件: 19 |
310 |
Rhnaglu radiolabelled |
- |
- |
- |
- |
1件: 19 |
311 |
Rhnaglu-igf2 |
Insulin-like growth factor ii |
- |
- |
- |
1件: 19 |
312 |
Rimiducid |
- |
- |
- |
- |
5件: 19, 65, 284, 285, 326 |
313 |
Rivogenlecleucel |
- |
- |
- |
- |
4件: 19, 65, 284, 285 |
314 |
Rp 103 |
- |
- |
- |
- |
2件: 8, 19 |
315 |
Rp103 |
- |
- |
- |
- |
2件: 8, 19 |
316 |
Rp103 q12h |
- |
- |
- |
- |
1件: 19 |
317 |
Rvx000222 |
- |
- |
- |
- |
1件: 19 |
318 |
Saf-301 |
- |
- |
- |
- |
1件: 19 |
319 |
Saline solution for injection |
- |
- |
- |
- |
1件: 19 |
320 |
Sar402671, gz402671 or gz/sar402671 |
- |
- |
- |
- |
2件: 19, 67 |
321 |
Sb-318 |
- |
- |
- |
- |
1件: 19 |
322 |
Sb-47171 |
- |
- |
- |
- |
1件: 19 |
323 |
Sb-47898 |
- |
- |
- |
- |
1件: 19 |
324 |
Sb-913 |
- |
- |
- |
- |
1件: 19 |
325 |
Sb-a6p-hrl donor vector |
- |
- |
- |
- |
1件: 19 |
326 |
Sb-idua |
- |
- |
- |
- |
1件: 19 |
327 |
Sbc-102 |
Sebelipase alfa |
D10377 |
1件: LIPA |
3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
1件: 19 |
328 |
Sbc-102 (sebelipase alfa) |
Sebelipase alfa |
D10377 |
1件: LIPA |
3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
1件: 19 |
329 |
Sbc-102 [sebelipase alfa] (1 mg/kg) |
Sebelipase alfa |
D10377 |
1件: LIPA |
3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
1件: 19 |
330 |
Sbc-103 |
- |
- |
- |
- |
1件: 19 |
331 |
Scaav9.u1a.sgsh |
- |
- |
- |
- |
1件: 19 |
332 |
Sebelipase alfa |
Sebelipase alfa |
D10377 |
1件: LIPA |
3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
1件: 19 |
333 |
Sham procedure control |
- |
- |
- |
- |
1件: 19 |
334 |
Shp611 |
- |
- |
- |
- |
1件: 19 |
335 |
Sobi003 |
Sobi003 |
- |
- |
- |
1件: 19 |
336 |
Sofosbuvir |
Sofosbuvir |
D10366 |
- |
- |
1件: 19 |
337 |
Somatropin |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
15件: 2, 3, 19, 46, 74, 75, 78, 96, 113, 193, 195, 265, 274, 276, 299 |
338 |
Somatropin (dna origin) |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 19 |
339 |
Sp 54 |
Pentosan polysulfate |
D05428 |
- |
- |
1件: 19 |
340 |
Sp54 |
Pentosan polysulfate |
D05428 |
- |
- |
1件: 19 |
341 |
St-920 |
- |
- |
- |
- |
1件: 19 |
342 |
Stem cell transplantation |
- |
- |
- |
- |
9件: 13, 19, 20, 46, 65, 90, 164, 234, 326 |
343 |
Taliglucerase alfa |
Taliglucerase alfa |
D09675 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
344 |
Thiotepa |
Thiotepa |
D00583 |
- |
- |
11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 |
345 |
Thiotepa--escalated dose |
Thiotepa |
D00583 |
- |
- |
4件: 19, 20, 65, 284 |
346 |
Thiotepa--single daily dose |
Thiotepa |
D00583 |
- |
- |
4件: 19, 20, 65, 284 |
347 |
Trappsol cyclo |
- |
- |
- |
- |
1件: 19 |
348 |
Treosulfan |
Treosulfan |
D07253 |
- |
- |
3件: 13, 19, 65 |
349 |
Tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
2件: 6, 19 |
350 |
Unrelated umbilical cord blood transplant |
- |
- |
- |
- |
1件: 19 |
351 |
Usan: sebelipase alpha |
- |
- |
- |
- |
1件: 19 |
352 |
Ux003 |
- |
- |
- |
- |
1件: 19 |
353 |
Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana |
- |
- |
- |
- |
1件: 19 |
354 |
Velaglucerase alfa |
Velaglucerase alfa |
D09029 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
355 |
Velmanase alfa |
Velmanase alfa |
D11024 |
1件: MAN2B1 |
2件: Lysosome, Other glycan degradation |
1件: 19 |
356 |
Velmanase alfa (e.g. lamazym) |
Velmanase alfa |
D11024 |
1件: MAN2B1 |
2件: Lysosome, Other glycan degradation |
1件: 19 |
357 |
Vimizim® (elosulfase alfa) |
Elosulfase alfa |
D10333 |
1件: GALNS |
3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
1件: 19 |
358 |
Vitamin d |
Vitamin d |
- |
- |
- |
18件: 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
359 |
Vorinostat |
Vorinostat |
D06320 |
11件: HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 |
15件: Alcoholism, Amphetamine addiction, Apelin signaling pathway, Cell cycle, Chronic myeloid leukemia, Epstein-Barr virus infection, Human papillomavirus infection, Huntington disease, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Notch signaling pathway, Pathways in cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Viral carcinogenesis |
2件: 19, 96 |
360 |
Vpriv |
Velaglucerase alfa |
D09029 |
1件: GBA |
4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
1件: 19 |
361 |
Vpriv ®, |
- |
- |
- |
- |
1件: 19 |
362 |
Vpriv® |
- |
- |
- |
- |
1件: 19 |
363 |
Vts-270 |
- |
- |
- |
- |
1件: 19 |
364 |
Vts270 |
- |
- |
- |
- |
1件: 19 |
365 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
366 |
Water |
Water |
D00001 |
- |
- |
18件: 2, 5, 6, 13, 17, 19, 35, 46, 53, 57, 63, 65, 67, 84, 97, 226, 278, 299 |
367 |
Zavesca |
Miglustat |
D05032 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
3件: 19, 256, 299 |
368 |
Zavesca (miglustat) |
Miglustat |
D05032 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
1件: 19 |
369 |
Zinc |
Zinc |
- |
- |
- |
4件: 2, 19, 171, 299 |